Other impact factors on DFS identified in the univariate analysis included tumor grade, size, ER, Ki-67, molecular subtype, and adjuvant endocrine therapy usage (all P<0.05; Supplementary Table S2). The gene discussed is ESR1; the disease is neoplasm.